An Examination of Acceptability of HPV Vaccination among African American Women and Latina Immigrants
- 1 October 2007
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Women's Health
- Vol. 16 (8) , 1224-1233
- https://doi.org/10.1089/jwh.2006.0175
Abstract
This study examined the acceptability of preventive human papillomavirus (HPV) vaccination among Latina immigrants and African American women through eight focus groups (n = 55, 28 Latinas and 27 African Americans). Latinas were between 17 and 39 years old (x = 27.9) and African Americans between 19 and 39 (x = 24.3). Approximately 86% of Latinas and 7% of African Americans were married or living with a partner; 10.7% of Latinas and 53.8% of African Americans reported having health insurance; 60.7% of Latinas and 77.8% of African Americans had never heard about HPV. Following a brief presentation about cervical cancer and HPV, participants were questioned about the acceptability of a preventive HPV vaccine. Overall, both groups indicated that an HPV preventive vaccine would be acceptable. However, African Americans were more skeptical, citing concerns about effectiveness and side effects. Another African American concern was whether vaccinated women would perceive themselves as being protected from HPV, leading them to increased promiscuity or unprotected sex. African Americans' motivating factors for vaccine use included receiving education/information about the vaccine, affordable prices, good results in trials, and knowing others who had already gotten vaccinated. Latina immigrants, on the other hand, unanimously stated that they would get the vaccine. However, they believed that multiple credible sources of information (educational talks, doctor's office, television, churches, and other women) needed to promote the vaccine before the Latino community at large would accept it. These findings suggest that unique educational strategies need to be developed, based on the needs and perceptions of the targeted audience, in order to achieve wide-spread acceptability of this vaccine.Keywords
This publication has 33 references indexed in Scilit:
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial NeoplasiaObstetrics & Gynecology, 2006
- Prevention of cervix cancerCritical Reviews in Oncology/Hematology, 2000
- Acceptability of Human Papillomavirus ImmunizationJournal of Women's Health & Gender-Based Medicine, 2000
- A case-control study of human papillomavirus and cervical squamous intraepithelial lesions (SIL) in Harris County, Texas: differences among racial/ethnic groupsCadernos de Saude Publica, 1998
- Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial NeoplasiaJNCI Journal of the National Cancer Institute, 1993
- Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and yearBritish Journal of Cancer, 1992
- Differences in cancer-risk-related behaviors in Latino and Anglo adultsPreventive Medicine, 1991
- Determinants of late stage diagnosis of breast and cervical cancer: the impact of age, race, social class, and hospital type.American Journal of Public Health, 1991
- Ethnicity, survival, and delay in seeking treatment for symptoms of breast cancerCancer, 1985